---
title: "These 15 S&P 500 stocks could be contrarian -2-"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/287080606.md"
description: "Eli Lilly (LLY) has a forward P/E of 25.4, higher than the healthcare sector and S&P 500 averages, justified by strong growth projections. Insulet (PODD) also in healthcare, has a lower forward P/E but higher CAGR projections for revenue and EPS compared to Lilly."
datetime: "2026-05-20T14:05:52.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/287080606.md)
  - [en](https://longbridge.com/en/news/287080606.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/287080606.md)
---

# These 15 S&P 500 stocks could be contrarian -2-

Eli Lilly's (LLY) forward P/E is 25.4, which is well above those of the healthcare sector and the full S&P 500 (which is at the bottom of the sector list on the second table). But this premium valuation may be well-justified by Lilly's growth projections.

Insulet (PODD) is also in the healthcare sector and its forward P/E is lower than that of Lilly, while its CAGR projections for revenue and EPS are higher than those for Lilly.

Click on the tickers for more about each company.

Read: Tomi Kilgore's detailed guide to the information available on the MarketWatch quote page

Don't miss: These 10 tech stocks have been models of consistency for a decade - none are chip stocks

\-Philip van Doorn

This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

05-20-26 1005ET

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [PODD.US](https://longbridge.com/en/quote/PODD.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IHI.US](https://longbridge.com/en/quote/IHI.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XHE.US](https://longbridge.com/en/quote/XHE.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)

## Related News & Research

- [Eli Lilly (LLY) Is Up 6.0% After Obesity Drug Data And $4.5B Manufacturing Push - Has The Bull Case Changed?](https://longbridge.com/en/news/286629257.md)
- [Eli Lilly (LLY) Is the Face of the Obesity Boom. Has the Market Already Priced It In?](https://longbridge.com/en/news/286727957.md)
- [Engage Bio Acquired by Lilly to Accelerate Development of Non-Viral Genetic Medicines](https://longbridge.com/en/news/287077005.md)
- [Trump purchased Eli Lilly stock as policies favored its drugs](https://longbridge.com/en/news/286791021.md)
- [<![CDATA[Eli Lilly Enters $202 Million Agreement to Acquire Engage Bio]]>](https://longbridge.com/en/news/287099809.md)